For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of researchers have discovered that this workhorse protein, called cereblon, in ...

Statista, a global data company that publishes insights for 170 industries, projects four cancer therapies will be among the top 10 best-selling pharmaceutical products in the U.S. this year.  The ...

People at risk of colorectal cancer are sometimes prescribed daily aspirin. Scientists look into that preventative possibility and safety for everyone.

Obesity is now linked to at least 13 types of cancer, making it one of the most preventable cancer risk factors in the United ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

Chesterbrook's Persevere Therapeutics marked its emergence from stealth mode with a completed equity financing and product acquisition.

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease. Published in Translational ...

Are time commitments related to cancer care toxic? Depends on who you ask.The term “time toxicity” has become cancer jargon over the past few years, sparking research into how much time patients spend ...

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.

Roche Holding shares fell after the company said a late-stage study for an experimental breast-cancer treatment missed its primary objective. The results of the clinical trial mark a setback for the ...

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...